As part of its Cancer Moonshot initiative, the Biden administration will launch a private sector pilot program by the end of the year to address pediatric cancer drug shortages.

Health care providers, pharmaceutical companies and nonprofit organizations will develop standards to identify shortage risks for seven pre-qualified pediatric cancer drugs, according to an Oct. 28 press release from the administration.

The goal of the pilot program is to avoid disruptions in patient care and medication distribution for children and families facing cancer, the release said. The End Drug Shortages Alliance will publish a report on the program’s results in 2025, when the pilot ends.

Healthcare providers participating in the pilot program include Philadelphia-based National Children’s Hospital, Washington, D.C., Children’s Mercy Kansas City (Mo.), Cincinnati Children’s Hospital Medical Center, Stanford (Calif. ) Medicine Children’s Health, Memphis, Tennessee. St. Jude Children’s Research Hospital, based in Houston, and Texas Children’s Hospital, based in Houston.

Pharmaceutical companies Cencora and Morris & Dickson, as well as nonprofits Angels for Change, Children’s Hospital Association and US Pharmacopeia will also participate.